


FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 8648.61USWO	Application Number: 09/011,940
			Applicant: NAUCK ET AL.	
			Filing Date: 02/20/1998	Group Art Unit: UNKNOWN

1627

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BC	5,118,666	06/02/1992	Habener	514	12	—
BC	5,120,712	06/09/1992	Habener	514	12	—
BC	5,364,838	11/15/1994	Rubsamen	514	3	—
BC	5,383,848	01/24/1995	Hillman et al.	604	20	—
BC	5,487,898	01/30/1996	Lu et al.	424	430	2/9/94
	5,512,519	04/30/1996	Chen et al. → DVPE			
BC	5,545,618	08/13/1996	Buckley et al.	514	12	9/21

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
BC	0 619 322 A2	10/12/1994	EP				
BC	WO 93/11799	06/24/1993	PCT				
BC	WO 93/18785	09/30/1993	PCT				
BC	WO 97/07814	03/06/1997	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Amland, P.F. et al., "Effects of Atropine on GIP-induced Insulin and Pancreatic Polypeptide Release in Man", <i>Scand J. Gastroenterol.</i> , 20:321-324 (1985).
BC	Baer, A.R. et al., "Effects of Gastric Inhibitory Polypeptide in the Response to Prolonged Parenteral or Enteral Alimentation in Rats", <i>Diabetes</i> , 34(11):1108-1112 (November 1985).
BC	Guo, Jian-Hwa et al., "Bioadhesive Polymer Buccal Patches For Buprenorphine Controlled Delivery: Solubility Consideration", <i>Drug Development and Industrial Pharmacy</i> , 21(17):2013-2019 (1995).
BC	Gutniak, M. et al., "Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet", <i>Diabetes Care</i> , 19(8):843-848 (August 1996).
BC	Leone-Bay, A. et al., "Microsphere Formation in a Series of Derivatized α -Amino Acids: Properties, Molecular Modeling, and Oral Delivery of Salmon Calcitonin", <i>Journal of Medicinal Chemistry</i> , 38(21):4257-4262 (1995).
BC	Schmidt, W. et al., "Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets", <i>Diabetologia</i> , 28(9):704-707 (September 1985).

EXAMINER	BC, Clev	DATE CONSIDERED	5/27/00
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 089187/0115	SERIAL NO. 09/011,940
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT Michael NAUCK et al.	
		FILING DATE 2/20/98	GROUP ART UNIT 1627

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
<i>MM</i>	A1	6,006,753	Dec. 28, 1999	Efendic	128	898	<i>8/97</i>
<i>BL</i>	A2	5,846,937	Dec. 8, 1998	Drucker	514	12	<i>3/97</i>
<i>BC</i>	A3	5,512,549	Apr 30, 1996	Chen et al.	514	12	
<i>PR</i>	A4	5,424,286	Jun. 13, 1995	Eng	514	2	<i>—</i>
<i>MM</i>	A5	5,912,229	Jun 15, 1999	Thim et al.	514	12	
<i>MM</i>	A6	5,116,666	Jun 2, 1992	Habener	514	12	

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
A7	99/29336	Jun 17, 1999	WIPO				
A8	98/08531	Mar. 5, 1998	WIPO				
A9	98/08873	Mar. 5, 1998	WIPO				
A10	99/40788	Aug. 19, 1999	WIPO				
A11	98/20895	May 22, 1998	WIPO				
A12	98/19698	May 14, 1998	WIPO				
A13	97/39031	Oct. 23, 1997	WIPO				
A14	91/11457	Aug. 8, 1991	WIPO				
A15	97/31943	Sep. 4, 1997	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A16	Rabinovitch et al., Endocrinology 94:1139 (1974)	
A17	Dupre et al., Cndocrinol. Metab. 37:826(1973)	
A18	Gutniak et al., New England Journal of Medicine 326:1316	
A19	Nathan et al., Diabetes Care 15:270 (1992)	
A20	Nauck et al., Diabetologia 36:741 (1993)	
A21	Hargrove et al., Metabolism 44:1231 (1995)	

*B. cover**- 2nd 200*

	A22	Gutniak et al., Diabetes Care 17:1039 (1994)
	A23	Ranganath et al., GUT 38:916 (1996)
	A24	Pierluissi et al., Acta Cientifica Venezolana 46(2):89 (1995)
	A25	Creutzfeldt et al., Diabetes Care 16:580 (1996)
	A26	Shaw et al., Annals of Surgery 209(N1):63 (1989)
	A27	Suzuki et al., Endocrinology 125:3109 (1989)
	A28	Rowland et al., Nutrition 12:626 (1996)
	A29	Sachs et al., Chirurg 59:24 (1988)
	A30	Mizock et al., American Journal of Medicine 98:75 (1995)
	A31	Deacon et al., Diabetes 44:1126 (1995)
	A32	Navarro et al., J. Neurochemistry 67:1982 (1996)
	A33	Turton et al., Nature 379:69 (1996)
	A34	Tang-Christensen et al., American Journal of Physiology 271:R848 (1996)
	A35	Barragan, J.M. et al., Regul. Peptides 67:63 (Nov 1996)
	A36	Barragan et al., American Journal of Physiology 226 E459 (1994)
	A37	O'Shea et al., Neuroreport 7:830 (1996)
	A38	Japanese Patent Abstract, JP8268908, Drugs for maintaining the function of gastrointestinal mucosa – contain Gastrointestinal hormone..., 10/96, Dialog (R) File 351:Derwent WPI 96-514913/199651
	A39	Japanese Patent Abstract, JP5207846, Fermented milk and lactobacilli beverage easily..., 8/93 Dialog (R) File 351:Derwent WPI 93-297440/199338

EXAMINER

Barragan

DATE CONSIDERED

RECEIVED

sh23202

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.